Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in Indonesia

NCT05933278 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05933278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05933278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in Indonesia
Lead sponsor
PT Bio Farma
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2023
Completion date
September 5, 2024
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19